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Abstract: The Mediterranean diet (MD) has been reported to have beneficial effects on breast cancer
and cardiovascular diseases. Recently, microRNAs (miRNAs) have been suggested as biomarkers for
the diagnosis and disease prognosis in cancer and cardiovascular diseases. We evaluated the influence
of the MD on the plasma-derived extracellular vesicle miRNA signature of overweight breast cancer
survivors. Sixteen participants instructed to adhere to the MD for eight weeks were included in this
study. To curate differentially expressed miRNAs after MD intervention, we employed two methods:
significance analysis of microarrays and DESeq2. The selected miRNAs were analyzed using ingenuity
pathway analysis. After an eight-week intervention, body mass index, waist circumference, fasting
glucose, fasting insulin, and homeostatic model assessment for insulin resistance were significantly
improved. Expression levels of 798 miRNAs were comprehensively analyzed, and 42 extracellular
vesicle miRNAs were significantly differentially regulated after the eight-week MD (36 were up and 6
were down-regulated). We also identified enriched pathways in genes regulated by differentially
expressed 42 miRNAs, which include signaling associated with breast cancer, energy metabolism,
glucose metabolism, and insulin. Our study indicates that extracellular vesicle miRNAs differentially
expressed as a result of the MD might be involved in the mechanisms that relate to cardiometabolic
risk factors in overweight breast cancer survivors.
Keywords: mediterranean diet; breast cancer survivor; microRNA; obesity
1. Introduction
Worldwide, breast cancer is the most commonly diagnosed cancer and leading cause of female
cancer death [1]. Recent advances in treatment and improvements in early detection and screening
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for this disease continue to increase the number of breast cancer survivors [2]. Given the decline of
the mortality rate of breast cancer patients [2], survivorship care after breast cancer is an important
issue not only for oncologists but also for general practitioners [3]. Obesity, physical inactivity, and
unhealthy diet are known to increase mortality of breast cancer survivors [4,5]. Because breast cancer
and cardiovascular diseases (CVD) share common risk factors, the risk of CVD is higher in older
breast cancer survivors [6]. Therefore, weight management, sufficient physical activity, and health
diet pattern are crucial for decreasing cancer mortality and CVD among breast cancer survivors [6,7].
The Mediterranean diet (MD) is characterized by a high intake of vegetables, fruits, nuts, legumes,
whole grains, and olive oil, as well as a moderate consumption of fish and poultry, and a low intake
of sweets and red meat [8,9]. MD beneficial effects in metabolic diseases, such as CVD, various
cancers, and obesity have been extensively documented over the past decade [8,10,11]. In addition,
several studies have reported that the MD had a primary prevention effect in breast cancer [12–15].
Toledo et al. [12] found that a MD supplemented with extra virgin olive oil reduced the risk of breast
cancer in the Prevención con Dieta Mediterránea (PREDIMED) trial. The Singapore Chinese Health
Study of an Asian cohort showed that the MD prevented the incidence of breast cancer in overall
population and postmenopausal women [15]. The California Teachers Study demonstrated that a high
index of MD was associated with a low risk of breast cancer incidence in postmenopausal women [14].
The extracellular vesicle (EV), a membrane-derived vesicle, is involved in cell-to-cell
communication and contains various molecules, such as lipids, mRNAs, and microRNAs (miRNAs) [16].
EV miRNA has sufficient properties to be a useful biomarker which is detected preferably before the
clinical symptoms have appeared [17]. Previous studies have shown alteration of miRNAs after a
relatively short duration of diet intervention and their associations with metabolic parameters [18,19].
Ortega et al. found circulating miRNA profile changes from 30 participants who consumed nuts
(Polyunsaturated fatty acids (PUFAs)-enriched diet) for 8 weeks [18]. Marques-Rocha et al. reported
that expression levels of inflammation-related miRNAs were changed after MD-based weight loss
program in individuals with metabolic syndrome [19]. However, we still have not fully understood
the mechanisms that change the miRNA expressions after MD intervention in human. Previous
studies have analyzed only a small number of candidate genes curated from the knowledge-based or
local biological function-based miRNA pools [19]. Therefore, in this study, we aimed to evaluate the
influence of the MD on cardiometabolic changes and EV miRNA signature in breast cancer survivors
by screening more than 700 significant miRNAs.
2. Methods
2.1. Study Overview and Participants
The original randomized controlled trial “Effects of Mediterranean diet and naltrexone/bupropion
treatment on weight loss in overweight or obese breast cancer survivors” (ClinicalTrials.gov number,
NCT03581630) was designed as three arms; the first group was overweight breast cancer survivors
receiving the MD plus naltrexone/bupropion medication; the second group was overweight breast
cancer survivors receiving the MD alone; and the third group was overweight non-cancer patients
receiving the Mediterranean diet plus naltrexone/bupropion medication. To rule out the effect of the
drug, we included twenty overweight breast cancer survivors who received the MD alone into the
sub-study of EV miRNA expression before and after the intervention. All participants agreed to the
measurements of the circulating EV miRNA in their samples.
Inclusion criteria were as follows: breast cancer survivors who were diagnosed with breast cancer
stage I–III and who completed any cancer treatment at least 5 years ago, aged 20–65 years, obese
(BMI ≥ 25 kg/m2), or overweight 25 kg/m2 ≥ BMI ≥ 23 kg/m2 with at least one metabolic risk factor
with Asian criteria. The participants who experienced cancer recurrence or metastasis were excluded.
The MD intervention was performed for 8 weeks. The participants received dietary advice regarding
the MD from a qualified nutritionist during a 30 min baseline visit. The subjects also received daily
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feedback about their food consumption from the researchers through a mobile messenger. Before
and after MD intervention, the degree of adherence to the MD was measured using the modified
13-item questionnaire Mediterranean diet screener (excluding red wine consumption) developed by
the PREDIMED study group [8,20]. Samples from four participants failed quality control procedures;
we conducted full analysis of data from 16 out of 20 participants enrolled initially. This study was
conducted at the Gangnam Severance Hospital (Seoul, South Korea) according to the principles of
the International Declaration of Helsinki. The study was approved by the institutional review board
(3-2017-0097) and written informed consents were obtained from all participants before the trial.
2.2. Extracellular Vesicle RNAs Measurement
EV RNA was extracted from 1.5 mL of plasma by using an exoRNeasy Serum/Plasma kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruction. Exogenous spike-in cel-miR-39-3p was
added to each sample during the extraction as loading control. After isolation, samples were cleaned
and concentrated (Zymo Research, Irvine, CA, USA), then concentrations were measured with Qubit
(Thermo Fisher Scientific, Waltham, MA, USA). All samples were loaded into a NanoString human
miRNA panel (NanoString, Seattle, WA, USA) to measure the miRNA expression at pre-and post- MD
intervention. miRNA expression level of each sample was normalized with the expression value of
spike-in and housekeeping genes on nSolverTM (NanoString, Seattle, WA, USA). We presented the
characteristics of plasma EVs in Appendix A Figure A1 and effects of MD on EVs characteristics in
Appendix A Figure A2. The sizes and concentrations of EVs were not significant in both groups.
2.3. Identification of Differentially Expressed miRNAs
In order to curate differentially expressed miRNAs after MD intervention, we employed two
methods: significance analysis of microarrays (SAM) and DESeq2. The SAM approach proposed by
Tusher et al. [21] estimates false discovery rate (FDR) by applying the permutation method. We used the
“SAM” function with setting “Two class paired” and “nperms (number of permutation) = 500” in samr
package [21]. DESeq2 uses shrinkage estimation for dispersions and fold changes to improve stability
and interpretability of estimates [22]. We used the “DESeq()” function in the DESeq2 package [22].
For both SAM and DESeq2, we set the adjusted p-value (FDR) to be below 0.05 and |log2(fold change)|
to be over 1 as the cut-offs for differentially expressed miRNAs.
Given that we analyzed relatively few samples (n = 16), even one sample with outliers could over-
or underestimate the effects of the MD intervention. We observed that 14 miRNAs at baseline point
had standard deviation values over 100, indicating that there were outliers that could indeed mask
the significant effects. To overcome the limitation of the relatively small sample size, we performed
bootstrapping with the two described methods, SAM and DESeq2, as follows:
Step (1): Sixteen samples (same number in all subjects) were randomly selected with replacement.
Step (2): Differentially expressed miRNAs were curated by using SAM and DESeq2 with adjusted
p-value (FDR) < 0.05 and |log2(fold change)| > 1.
Step (3): The above steps were repeated 100 times, yielding a list that included selected miRNAs.
2.4. Curation of miRNA Target Genes
The selected miRNAs were analyzed by ingenuity pathway analysis (IPA; QIAGEN, Hilden,
Germany). Putative miRNA target genes were filtered based on the setting that included only
experimentally validated targets. For miRNA that targeted too many genes (>50), stricter criteria
(experimentally validated + highly confident prediction) were applied.
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2.5. Pathway Analysis
We performed pathway analysis for candidate genes by using Kyoto Encyclopedia of
Genes and Genomes (KEGG) [23] and Gene Ontology (GO) [24] databases and the DAVID tool
(https://david.ncifcrf.gov/) [25]. A pathway was deemed to be significantly enriched in genes targeted
by miRNAs if FDR < 0.05.
3. Results
3.1. Clinical Characteristics of the Study Population
The Severance Mediterranean Diet team (SeMeD) performed the dietary intervention for breast
cancer survivors, and 11 cardiometabolic indices were measured (Table 1).
Table 1. Baseline characteristics of study participants (n = 16).
Body Composition Patients’ Data Nutritional Status Patients’ Data
Age (Years) 55.2 ± 7.2 Total energy intake(kcal) 1646 ± 411
SBP (mmHg) 126.4 ± 13.4 Carbohydrate (%) 51.4 ± 14.7
DBP (mmHg) 83.8 ± 11.9 Protein (%) 16.3 ± 2.0
Hear rate (bpm) 75.0 (68.3, 80.8) Fat (%) 28.8 ± 10.6
Metabolic parameters SFA (%) 5.2 (2.1, 7.3)
BMI (kg/m2) 26.0 ± 1.3 MUFA (%) 6.1 (4.1, 8.7)
Waist circumference(cm) 87.8 ± 5.6 PUFA (%) 8.7 (5.0, 14.8)
Skeletal muscle (kg) 22.2 (21.5, 22.9) Omega-6 (%) 0.5 (0.1, 1.6)
Fat mass (kg) 23.4 ± 3.5 Omega-3 (%) 2.2 (0.8, 9.3)
Fat percentage (%) 36.3 ± 4.3 Hormone status
GLTEQ score (MET-h/week) 9.3 (0, 28) ER−/PR− 4 (25%)
Glucose (mg/dL) 90.1 ± 12.0 ER+/PR− 2 (12.5%)
Insulin (mU/L) 8.1 ± 2.8 ER−/PR+ 1 (6.25%)
HOMA-IR 1.8 ± 0.8 ER+/PR+ 9 (56.25%)
Total cholesterol (mg/dL) 198.0 ± 26.3 Staging
Triglyceride (mg/dL) 148.4 ± 67.6 IA 9(56.3%)
HDL cholesterol (mg/dL) 56.0 ± 9.9 IIA 4(25%)
LDL cholesterol (mg/dL) 112.3 ± 24.3 IIB 3 (18.7%)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis
model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; GLTEQ,
Godin Leisure-Time Exercise Questionnaire; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; ER, estrogen receptor; and PR, progesterone receptor. Data are presented as mean
± standard deviations for continuous variables with normal distribution or median (25th, 75th) for continuous
variables with markedly skewed distribution or number (percentage) for categorical variables.
After an eight-week intervention, body mass index (BMI), waist circumference (WC), fasting
glucose, fasting insulin, and homeostatic model assessment for insulin resistance (HOMA-IR) were
significantly reduced (Figure 1A–E). In particular, 13 of the 16 participants had lower BMI and smaller
WC after the eight-week MD intervention. Furthermore, 14 of the 16 participants had lower insulin
levels, whereas 15 of the 16 participants showed decreased levels of fasting glucose and HOMA-IR.
The Mediterranean Diet Screener (MDS) score (Figure 1F) was significantly improved after 8 weeks
of the intervention (7.8 ± 1.9 before MD and 10.7 ± 1.5 after MD, p < 0.001), indicating improved
adherence to MD in all participants.
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Figure 1. Changes in metabolic indices induced by the MD in overweight breast cancer survivors.
The panels annotated by the capital letters (A–F) represent box-whisker plots of metabolic indices before
and after intervention. p-values were calculated by the paired Student’s t-test after Kolmogorov–Smirnov
test. The panels annotated by the lowercase letters (a–f) represent scatter plots of the same data as in
(A–F). Red triangles indicate values that decreased after the intervention. Black circles indicate values
that increased after the intervention.
3.2. Plasma Extracellular Vesicle miRNA Changes and Mediterranean Diet
First, extracted extracellular vesicles were confirmed by an electron microscope and Nanoparticle
Tracking Analysis (NTA) (Appendix A Figure A1). NTA showed that the average size and concentration
of extracellular vesicles were not significantly different between pre-and post-MD (Appendix A
Figure A2).
We screened 798 miRNAs and measured its fold changes between pre- and post-MD intervention
in 16 subjects (798 × 16 matrix). We applied two linear regression models with one setting each miRNA
as the dependent variable and WC as the independent variable, and the other treating “WC + MDS” as
the independent variable. We determined two sets of 798 R2 values, which reflected the fractions of
total variation in expression of 798 miRNAs (dependent variable) that could be explained by WC and
“WC + MDS” annotations. Similar analyses were also performed for the effects of BMI and HOMA-IR
with and without MDS scores.
Figure 2 shows R2 values for the effects of WC, BMI, and HOMA-IR with and without MDS scores.
The combined effects of WC, BMI, HOMA-IR, and MDS scores on miRNA changes were significantly
higher than the effects of WC, BMI, and HOMA-IR without MDS scores (all p-values < 0.001),
respectively. These results implied that MD had a crucial contribution to transcriptomic alterations
independent of WC, BMI, or HOMA-IR in breast cancer survivors.














Figure 2. Proportions of variance in miRNA expression (R2) explained by WC, BMI, and HOMA-IR
respectively and in combination with MDS scores. MiRNA, micro RNA; WC, waist circumference;
BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; and MDS,
Mediterranean diet screener.
3.3. Identification of Expressed Extracellular Vesicle miRNAs
Figure 3 shows up- or downregulated miRNAs selected by the “Significance Analysis of
Microarrays” (SAM) tool with bootstrapping. The 70 miRNAs upregulated by MD were selected with
different frequencies; for example, hsa-miR-144-3p was selected 100 times, whereas hsa-miR-892a was
selected only once (Figure 3A). In the same way, 9 downregulated miRNAs were selected (Figure 3C).
By using DESeq2 with bootstrapping, 31 upregulated and 15 downregulated miRNAs were selected,
respectively (Figure 3B,D).
The rapidly decreasing point for the 70 upregulated miRNAs selected using SAM was at the
frequency value of 51 (Figure 3A). In the same way, we determined frequency values of 44 and 71 as
thresholds for upregulated miRNAs (DESeq2) and downregulated miRNAs (DESeq2), respectively
(Figure 3B,D). Finally, 36 and 23 up-regulated miRNAs, as well as four and six downregulated miRNAs,
identified using SAM and DESeq2, respectively, were selected (Figure 3E). The list of 36 up-regulated
miRNAs selected using SAM included all 23 miRNAs from the DESeq2 list. Furthermore, the six
downregulated miRNAs identified using DESeq2 included all miRNAs selected using SAM. Detailed
information about the selected miRNAs is presented in Table S1.
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Figure 3. Differentially regulated miRNAs after MD identified using SAM and DESeq2. (A) Up-regulated
miRNAs identified using SAM. (B) Up-regulated miRNAs identified using DESeq2. (C) Down-regulated
miRNA identified using SAM. (D) Down-regulated miRNAs identified using DESeq2. (E) Numbers of
miRNAs selected using both SAM and DESeq2.
3.4. Extracellular Vesicle miRNAs and Their Target Genes
To identify the genes targeted by the selected miRNAs, we used QIAGEN Ingenuity Pathway
Analysis (IPA) software, taking into account only experimentally validated entries. As a result,
240 genes were identified as target genes of the 14 miRNAs that were altered by the MD (Table 2).
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Table 2. Changed miRNAs and target genes by ingenuity pathway analysis (IPA).
MicroRNAs Log2(FC) p Value Putative Target Genes by IPA
hsa-miR-122-5p 1.095 <0.001
AACS, ADAM17, AKT3, ALDOA, ANK2, ANXA11, AP3M2,
ATP11A, ATP1A2, BACH2, BCKDK, BCL2L2, CCNG1, CD320,
CERS6, CLDN18, CS, DSTYK, DUSP2, EGLN3, ENTPD4,
FAM117B, FOXJ3, FOXP1, FUNDC2, G6PC3, GALNT10, GPX7,
GYS1, HJV, MAPK11, MECP2, MEP1A, NCAM1, NDRG3,
NFATC1, NFATC2IP, NUMBL, OSMR, PALM, RAB11FIP1,
RAB6B, RABIF, SLC35A4, SLC7A1, SLC7A11, TBX19, TMED3,
TMEM50B, TPD52L2, TRIB1, TRPV6, TTYH3, UBAP2, XPO6
hsa-miR-429 1.145 <0.001
BAP1, ELMO2, ERBIN, ERRFI1, FHOD1, FOXF2, GEMIN2,
GSE1, KLHL20, MARCKS, PLCG1, PPM1F, PTEN, PTPN12,
PTPN13, PTPRD, RERE, WASF3, WDR37, ZEB1, ZEB2, ZFPM2
hsa-miR-324-5p 1.003 <0.001 GLI1, RUNX1, SMO, SRF
hsa-miR-378d 0.933 <0.001 IGF1R, ODC1, SUFU, TUSC2
hsa-miR-483-5p 1.019 <0.001 ALCAM, ARHGDIA
hsa-miR-515-3p 0.89 <0.001 BCL11B, BCOR, BTG1
hsa-miR-519c-3p 1.007 <0.001 ABCG2, AR, PRKAA1
hsa-miR-144-3p 1.359 <0.001 ENPP6
hsa-miR-216a-5p 0.996 <0.001 PTEN
hsa-miR-217 1.308 <0.001 TRPS1
hsa-miR-495-3p 0.891 <0.001 ONECUT1
hsa-miR-504-5p 1.207 <0.001 VEGFA
hsa-miR-512-3p 1.403 <0.001 CFLAR
hsa-let-7a-5p −3.794 <0.001
AARSD1, ACP1, ADGRG1, AGO4, AKAP8, ANAPC1,
ATAD3B, ATP6V0A1, ATP6V1F, AURKB, BCL2L1, BCL7A,
BMP2K, BSG, CALCOCO2, CAPG, CARHSP1, CASP3,
CCND1, CDC25A, CDIPT, CDK6, CDKAL1, CEMIP2,
CHMP2A, CIAO2A, COIL, COL1A2, COMMD9, CSDE1,
CSNK1D, DAD1, DHX57, DICER1, DOCK5, DRD3, DSP,
DUSP12, DUSP23, EIF3J, EIF4G2, F2, FADS2, FANCD2,
FNDC3A, GAK, GEMIN7, GRPEL2, GTPBP3, GYS1, HMGA1,
HMGA2, Hmga2, HMOX1, HYOU1, IFIT5, IFRD1, IGF2BP1,
IGF2BP2, IGF2BP3, IPO4, ITGB3, KCNJ16, KLK10, KRAS,
KRT19, LIN28A, MARS2, MED28, MLLT1, MRM1, MRPS24,
MRPS33, MTPN, MTRR, MYC, NEDD4, NF2, NRAS, NXN,
OTULINL, PGRMC1, POLD2, POLR2C, POM121/POM121C,
PPP1R7, PRDM1, PRIM1, PRRC2A, PTGS2, PXDN,
RABGAP1L, RAS, RBM19, RDH10, RHOB, RHOG, RPP38,
RRP8, RTCA, SCYL1, SEPT3, SIGMAR1, SLC1A4, SLC25A1,
SLC25A13, SLC25A24, SLC25A32, SLC38A1, SMC1A, SMOX,
SNAP23, SPCS3, SPRYD4, SYPL1, TAF9B, TAGLN, TGFBR1,
THBS1, TLR4, TPM2, TRIM71, TRMT1, TTC9C, TUSC2, TYMS,
UGT8, UHRF1, VIM, VPS39, WNT1
In the pathway analysis, 99 genes targeted by 13 up-regulated miRNAs were enriched in 19 GO
pathways (Table S2). Figure 4A shows top five pathways involving genes targeted by up-regulated
miRNAs. The 131 genes targeted by one down-regulated miRNA were enriched in 27 GO and 2 KEGG
pathways (Table S3). Figure 4B shows top five pathways of the genes targeted by down-regulated
miRNAs (cytoplasm, membrane bounded organelle, microRNAs in cancer, cellular amide metabolic
process, and translation).
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Among the 48 pathways (19 + 29 pathways) overrepresented in sets of potential target genes,
we identified breast cancer-related pathways via literature search (Figure 4C,D). The 19 pathways
enriched in the genes targeted by up-regulated miRNAs were associated with multidrug resistance,
triple-negative breast cancer, and tamoxifen-induced estrogen receptor α functions (Table S2).
The 29 pathways enriched in the genes targeted by the down-regulated miRNAs were reported
to be associated with lapatinib-resistant breast cancer, triple-negative breast cancer, and invasive ductal
carcinoma (Table S3).
GO:0009653~anatomical structure morphogenesis
GO:0045944~positive regulation of transcription 
from RNA polymerase II promoter
GO:0045595~regulation of cell differentiation
GO:2000026~regulation of multicellular organismal 
                                                             development
GO:0006412~translation
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Figure 4. Top five pathways from annotations of target genes of differentially regulated miRNAs
after MD. (A) Top five pathways of the genes targeted by the up-regulated microRNAs, and (B)
down-regulated microRNAs. Horizontal bars in (A,B) indicate −log (p-value) calculated using IPA.
(C) Target genes regulated by the up-regulated microRNAs. (D) Target genes regulated by the
down-regulated microRNA hsa-miR-let-7a-5p.
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We curated genes related to obesity (n = 201), inflammation (n = 2229), insulin resistance
(IR, n = 175), and breast cancer (n = 3141) from the DigSee database [26]. Among the 240 genes
targeted by 14 altered miRNAs, 45 genes targeted by nine altered miRNAs were common with
inflammation-related genes from DigSee. The 5, 7, and 80 genes targeted by 2, 5, and 12 miRNAs were
common with IR-, obesity-, and BRCA-related genes, respectively. The detailed information about
these genes is provided in Table S4.
4. Discussion
In our study, we found that 16 overweight breast cancer survivors who were instructed to adhere
to the MD had significantly lower BMI, WC, fasting glucose, and HOMA-IR after 8 weeks on this
diet. In addition, despite the relatively short intervention time, the MD altered expression of tens of
miRNAs among the 798 miRNAs analyzed in our experiments. Differentially regulated miRNAs after
MD intervention are known to be related to obesity, inflammation, and insulin resistance.
Although the overall breast cancer mortality rate has been consistently decreasing, breast cancer is
still the most common cause of cancer death among women, and 30% of all women initially diagnosed
with early-stage breast cancer experience relapses at distant sites [27]. This risk is not only reflected by
the molecular cancer subtype, TNM stage, and cancer grade, but also by the tumor cell genetics [27].
To evaluate the risk for cancer recurrence more precisely, a number of non-invasive surveillance options
have been explored, ranging from diverse imaging tools to the analysis of body fluids with the aim of
detecting circulating tumor cells, tumor DNA, proteins, miRNAs, and extracellular vesicles [28,29].
Recently, there has been a growing interest in circulating miRNAs as cancer biomarkers due to
their stability and noninvasiveness [30]. miRNAs are noncoding RNAs that regulate the expression
of target genes at the posttranscriptional level and play crucial roles in cellular processes such as
cell differentiation, proliferation, and apoptosis [31]. In breast cancer, a number of miRNAs have
been identified as tumor suppressors or oncogenes, which have important effects on tumor initiation,
metastasis, and chemoresistance [30]. These results suggest that determination of certain miRNAs
may facilitate the diagnosis, disease prognosis, and treatment response predictions in breast cancer.
Besides unfavorable tumor characteristics, individual factors such as diet, exercise, and pre-existing
medical conditions also affect cancer recurrence and metastasis [32]. Obesity, chronic inflammation,
and insulin resistance are modifiable risk factors that contribute to the development of breast cancer
occurrence [32–35]. Controlling weight, exercising, and healthy eating could help lowering the risk of
breast cancer recurrence as well as protect from other chronic diseases, including CVD.
Accumulating evidence suggests that adherence to MD reduces the risk of breast cancer as well as
of obesity, metabolic syndrome, and CVD [12,13,36,37]. Anti-inflammatory and antioxidant effects of
MD conferred by extra virgin olive oil and high amounts of fiber and polyphenols have been regarded
as protective factors against breast cancer [19,38]. A meta-analysis of randomized controlled trials
revealed that MD consumption was associated with significant weight loss (mean difference, −1.75 kg;
95% confidence interval: −2.86 to −0.64 kg) and lower BMI (mean difference, −0.57 kg/m2, −0.93 to
−0.21 kg/m2) [36]. A recent PREDIMED-Plus study showed that MD with exercise for 1 year was
effective in decreasing cardiovascular risk factors, including WC, glucose, and insulin resistance (mean
differences−3.1 cm, −0.23 mmol/L, and−1.16) in overweight/obese older adults [37]. Similarly, BMI and
WC were significantly lower in the current study after an 8-week period on MD (mean differences: −0.87
and −3.93 cm), respectively. The levels of glucose and HOMA-IR were also significantly decreased by
MD (mean differences, −0.55 mmol/L and −0.59, respectively), which were comparable to the changes
seen after 1 year in the PREDIMED study.
A recent study revealed that Mediterranean-based nutritional intervention induced changes in
miRNAs expression levels [19]. Moreover, several studies have highlighted the significance of miRNAs
as potential therapeutic targets for obesity and metabolic disorders [39,40]. Thus, we hypothesized that
even short adherence to the MD pattern potentially affects the expression of miRNAs related to cancer
recurrence as well as provides metabolic benefits in overweight breast cancer survivors. Most previous
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studies analyzed few candidate miRNAs curated using knowledge-based selection (i.e., specific PCR
primers/probes), a strategy that could lead to biased information. In contrast, we comprehensively
analyzed a total of 798 miRNAs and revealed 36 and 6 miRNAs up- and downregulated, respectively,
after an 8-week MD. Although we screened miRNAs using Nanostring technology which detects
almost 800 selected miRNAs from total miRNAs (>2000), untested miRNA might be involved in
the effect of the MD. In addition, when MDS score was combined with WC, BMI, or HOMA-IR, the
explanatory power of these annotations on miRNA changes was significantly elevated in terms of R2
values. These results could suggest that adherence to MD, per se, causes beneficial miRNA changes in
breast cancer survivors.
In this study, EV miRNAs involved in breast cancer invasion and metastasis by regulating multiple
cellular processes were differentially regulated after MD intervention. Hsa-miR-122-5p was reported
to suppress syndecan-1 expression, inhibiting breast cancer cell mobility [41]. Hsa-miR-324-5p was
demonstrated to have different patterns of expression, depending on breast cancer type, and the
overexpression of this miRNA suppressed cancer cell growth and invasion [42]. Let-7 miRNA is
usually categorized as a tumor suppressor because it inhibits migration and invasion, as well as
epithelial-mesenchymal transition by regulating several oncogenes [43]. However, the role of let-7
as a tumor suppressor is controversial, and emerging data suggest that, counterintuitively, in some
situations, let-7 may act as an oncogene, increasing cancer migration, invasion, and expression of
genes associated with progression and metastasis [44]. Interestingly, in our analysis, hsa-let-7a-5p was
downregulated after the MD. These inconsistent signatures of let-7 can be attributed to the differences
in the study populations and methodologies used in different reports. Further studies are warranted to
explore let-7 targets and biological context-specific flexibility of let-7 functions.
EV miRNAs associated with energy metabolism, glucose metabolism, and insulin signaling were
also altered. Hsa-miR-329-3p was reported to be downregulated in obese hyperglycemic mice [45],
and hsa-miR-512-3p was shown to be involved in adipocyte browning [46]. DNA methylation of
CpG sites located in hsa-miR-216a-5p is altered in obese children [47]. Both hsa-miR-324-3p and
hsa-miR-324-5p, which were obtained from visceral adipose tissue, were also up-regulated after MD
intervention in our study and down-regulated in non-alcoholic fatty liver disease [48]. Targets of
dysregulated let-7 are known to contribute to glucose homeostasis and insulin signaling as well as cancer
pathophysiology [49–51]. However, the roles of let-7 functionally relevant targets in metabolic control
await further elucidation. Hsa-let-7a-5p is down-regulated in individuals with diabetes [50], whereas
pancreas-specific overexpression of let-7 in mice resulted in impaired glucose tolerance and reduced
pancreatic insulin secretion [49]. In contrast, we observed that hsa-let-7a-5p was downregulated
after MD, whereas glucose control and insulin resistance were improved. Global knockdown of the
let-7 family prevented impaired glucose tolerance and insulin resistance in obese mice [49], which
agrees with our findings. Therefore, further studies are required to clarify the exact physiological and
pathological roles of let-7 in aberrant metabolic processes.
The target genes of the 14 miRNAs altered by the MD were predicted using QIAGEN IPA
software and DigSee database. Among the 240 target genes selected by IPA, 80 breast cancer-related,
7 obesity-related, 5 IR-related, and 45 inflammation-related genes overlapped with those predicted
from the DigSee database. Among breast cancer-, inflammation-, and IR-related genes, the biological
events were “Gene expression”, “Mutation”, “Positive or Negative regulation”, and “Mutation”.
In obesity-related genes, the biological events were “Mutation”, “Gene expression”, “Positive
regulation”, and “Localization”. Due to the complex regulation of the target genes, more studies
are needed to verify the exact roles of various genes in relation to miRNA changes in breast
cancer pathophysiology.
To determine biological processes and molecular functions associated with miRNAs differentially
expressed as a result of the MD, we performed pathway analysis and identified several potentially
affected pathways related to breast cancer pathogenesis. We found several such pathways enriched in
genes targeted by upregulated miRNAs, which was consistent with previous studies; for example,
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the “regulation of developmental process (GO:0050793)” pathway was the key candidate pathway
related to breast cancer in Han Chinese women [52]. The “growth (GO:0040007)” and “regulation
of cell proliferation (GO:0042127)” pathways were reported to be related to triple-negative breast
cancer [53]. “Tissue development pathway (GO:0009888)” and “multicellular organismal development
pathway (GO:2000026)” were associated with genes altered in invasive breast cancer [54] and multidrug
resistance in MCF-7/MDR breast cancer cells [55]. Most pathways enriched in annotations of genes
targeted by downregulated miRNAs were associated with the pathogenesis and progression of breast
cancer: microRNAs in cancer [hsa05206] [56], translation [GO:0006412] [57], reproductive system
development [GO:0061458] [58], cell cycle [GO:0007049] [58], adherens junction [GO:0005912], and
anchoring junction [GO:0070161]) [59]. Although it is impossible to understand fully all biological
phenomena driving gene expression and phenotypic changes, our approach has a potential clinical
applicability and paves the way for future research on breast cancer prognosis.
Our study had several limitations. First, the weakness of this study was a relatively small
sample size without control group. This is a pilot study that used the subset of the following trial
(NCT 03581630). Currently, larger randomized controlled trials with two arms (breast cancer patients
taking the MD and those taking conventional diet) are ongoing. Second, the intervention period to
assess the effects of the MD on metabolic risk was short. However, we found significant beneficial
effects on metabolic parameters despite 8 weeks of MD intervention. Changes in the molecular
level support our findings. Third, due to the shortage of the sample for the further analysis, we
could not validate the expression levels of target gene and determine the directions of effect of
those miRNAs on target genes. Further confirmation of target gene expressions will be necessary.
However, we observed transcriptomic alterations, specifically, the miRNA signatures, indicating that
the perturbed or re-perturbed genetic changes in the form of miRNA molecules precede phenotypic
changes in breast cancer survivors [60]. To establish the direction of changes in target genes following
alterations in miRNA levels, the multi-omics approach, including transcriptomics and proteomics, will
be needed in the future.
5. Conclusions
We found that 8 weeks of the MD causes changes in the expression of EV miRNAs in overweight
breast cancer survivors. Differentially regulated miRNAs after MD intervention were related to obesity,
inflammation, and insulin resistance. Further exploration of the downstream of EV miRNA might
provide novel targets for preventing cancer recurrence in overweight breast cancer
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Figure A1. Characteristics of plasma extracellular vesicles (EVs). (A) Extracted plasma EVs were 
scanned by electron-microscopy. (B) Size and concentration of EVs were measured by NanoSight 300. 
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